Karman Stock: 12 Straight Red Days, Down 34%
A dozen down days for Karman stock have pushed it to a new low, but the underlying business metrics tell a complicated story.
Shares of Karman (KRMN) have fallen by a third, with the entire move coming in a straight line. The stock has now moved lower for 12 consecutive trading days, a slide that has erased about $2.8 billion from the company’s market value. That leaves its current valuation at about $5.4 billion.
For anyone holding the stock, the decline has pushed the price to about $41.09 a share, a new 52-week low.
The Streak Next To The S&P 500
- How Will Guidewire Software Stock React To Its Upcoming Earnings?
- How Will Samsara Stock React To Its Upcoming Earnings?
- Heico Stock Extends A 7-Day Losing Streak To An 8.4% Loss
- How Will Zscaler Stock React To Its Upcoming Earnings?
- 9 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8%
- Dycom Industries Stock: 11 Straight Red Days, Down 34%
Here is how KRMN stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | KRMN | S&P 500 |
|---|---|---|
| 1D | -0.9% | -0.7% |
| 12D (Current Streak) | -33.7% | -2.0% |
| 1M (21D) | -18.5% | 0.4% |
| 3M (63D) | -24.8% | 0.3% |
| YTD 2026 | -43.8% | 11.5% |
| 2025 | 16.4% | |
| 2024 | 23.3% | |
| 2023 | 24.2% |
What Do The Numbers Say About This Sell-Off?
The pressure on Karman appears to be its own. Over the same 12 trading days, the S&P 500 returned -2.0%, a fraction of the stock’s 34% cumulative loss. The market may be weighing a genuinely mixed fundamental picture. On one hand, revenue over the last twelve months grew 50.2%, far outpacing the S&P 500 median revenue growth of 8.3%.
On the other hand, its operating margin of 16.8% sits below the S&P 500 median of 18.5%. And even after the recent decline, the stock trades at a price-to-earnings multiple of 146.5, a steep premium to the median of 23.2 for the broader index.
How Should An Investor Interpret A Streak?
A long streak is information, not an instruction. It tells you that momentum and market attention are intensely focused on a stock, but it does not, by itself, tell you if the new price is right or wrong. The disciplined move is to treat the streak as a prompt to check your thesis.
The numbers here allow for that first look. An investor can ask whether the company’s high growth and current profitability are consistent with its valuation, even after this significant drop in price.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
Prefer the theme to this single name? Our ETF Scorecard shows how the aerospace & defense funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Falling Prices Test Conviction. Rules Do Not Flinch
A losing streak forces a choice on every holder: sell into weakness, average down, or freeze. All three are emotional answers to what should be an analytical question, and emotions priced at market open are expensive.
The Trefis High Quality (HQ) Portfolio takes the emotion out: about 30 quality businesses screened for the fundamentals that survive bad stretches, held and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the rules do the heavy lifting for you.